Evidence map›Paper›PMID 41522171›Full record

ArticleJournal of thoracic disease2025

Quantitative analysis for identifying molecular subtypes of small cell lung cancer via two-dimensional and three-dimensional contrast-enhanced computed tomography images: a preliminary study.

Xu Jiang, Li Liu, Meng-Wen Liu, Jiu-Ming Jiang, Si-Jie Hu, Jia-Liang Ren, Li Zhang, Jian-Xin Zhang, Lin Yang, Meng Li

Abstract read
In one paragraph

Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xu Jiang *Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Li Liu *Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Meng-Wen LiuDepartment of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Jiu-Ming JiangDepartment of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Si-Jie HuDepartment of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Jia-Liang RenDepartment of Pharmaceuticals Diagnostics, GE HealthCare, Beijing, China.
Li ZhangDepartment of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Jian-Xin ZhangDepartment of Medical Imaging, Cancer Hospital Affiliated to Shanxi Medical University/Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences, Taiyuan, China.
Lin YangDepartment of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Meng LiDepartment of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Small cell lung cancer (SCLC) comprises distinct molecular subtypes [neuroendocrine (NE) Methods: In this single-center retrospective study, we included 51 patients with resected SCLC (NE subtype n=39, non-NE n=12) between 2005 and 2016, all with preoperative CECT scans and known molecular subtype confirmed by immunohistochemistry. Radiomics features were extracted from arterial-phase CECT images using both a 2D (single largest cross-sectional slice) and 3D (whole tumor volume) segmentation of the primary tumor. Radiomics-based logistic regression models were trained to classify NE Results: The 2D radiomics model achieved an AUC of 0.806 (95% CI: 0.666-0.945) for distinguishing NE Conclusions: Quantitative analysis of CECT images via radiomics can noninvasively distinguish NE and non-NE molecular subtypes of SCLC. A simplified 2D radiomics approach performed comparably to 3D volumetric analysis for subtype classification and also demonstrated prognostic relevance. Radiomics could serve as a valuable adjunct for SCLC subtype identification and risk stratification, potentially guiding more personalized treatment decisions.

Indexed as

contrast-enhanced computed tomography (CECT)molecular subtypesquantitative analysisradiomicsSmall cell lung cancer (SCLC)

Identifiers

PMID41522171
PMCPMC12780446

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.